US FDA clears Camber Spine’s Siconus sacroiliac joint fixation system

181

The US Food and Drug Administration has granted Camber Spine Technologies 510(k) clearance for the Siconus sacroiliac joint fixation system.

Daniel Pontecorvo, founder and chief executive officer of Camber Spine, says, “When used with the Prolix sacroiliac joint fusion system, the combined solution offers a direct visualisation and insertion of a machined allograft spacer into the sacroiliac joint, followed by a lateral approach compression and fixation implants.”

The Siconus system is intended to provide fixation and stabilisation of large bones, including the sacrum and ilium. It is intended for use in skeletally mature patients as an adjunct to sacroiliac joint fusion in the treatment of the degenerative sacroiliitis, or sacroiliac joint disruptions.

Siconus was developed under a collaborative agreement with the Institute for Musculoskeletal Science & Education.